Asia-Pacific African Horse Sickness Treatment Market was worth USD xx billion in 2018 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2023. African horse sickness is caused by a virus of the genus Orbivirus belonging to the family Reoviridae which is highly infectious and deadly disease and it commonly affects horses, mules, and donkeys. This virus is commonly known as African Horse Sickness Virus. It is not directly contagious, but is known to be spread by insect vectors and can be caused by any of the nine serotypes of this virus. This disease has a mortality rate of 95% in horses, which are most susceptible to the disease, while mules and donkeys are less likely to African horse sickness disease.
Good vaccination program is the best preventive method for African horse sickness treatment. In addition, good nutritional program and regular deworming which forms an integral part of horse health. The affected horses are slaughtered usually, where the uninfected horses are vaccinated against the virus. These type of prevention programs are efficient and cost-effective way to prevent common infectious diseases in a horse.
Presence of guidelines and standard operating procedures for African horse sickness disease, rising in research and development programmes for various preventive vaccines, increasing awareness regarding vaccination of horses, rising healthcare infrastructure, increase in disposable income and technology innovations in medical sector are driving the growth of the market. However, multivalent vaccine which do not guarantee that the horses are completely protected from the African horse sickness and high vaccine cost are hampering the growth of the market.
The Asia-Pacific African Horse Sickness Treatment Market was segmented on the basis of clinical forms, diagnosis and region. On the basis of clinical form, the market is segmented into Dikkop or Cardiac form, Dunkop or Pulmonary form, horse sickness fever, mixed form. Depending on the diagnosis, the market is segmented into prevention treatment and diagnostic tests. The prevention treatment is sub-segmented into vaccines and diagnostic tests is sub-segmented into laboratory tests for viral antigens and serological tests. The laboratory tests for viral antigens segment is further divided into reverse-transcription PCR assays and enzyme-linked immunosorbent assays. The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific is the fastest growing market due to the emerging economies and rise in the awareness about the vaccination of the horses.
The key players doming the Asia-Pacific African Horse Sickness Treatment Market are Veterinary Serum and Vaccine Research Institute and Onderstepoort Biological Products SOC Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Clinical forms
5.1.1 Introduction
5.1.2 Dikkop or Cardiac form
5.1.3 Dunkop or Pulmonary form
5.1.4 Horse sickness fever
5.1.5 Mixed form
5.1.6 Y-o-Y Growth Analysis, By Clinical forms
5.1.7 Market Attractiveness Analysis, By Clinical forms
5.1.8 Market Share Analysis, By Clinical forms
5.2 Diagnosis
5.2.1 Introduction
5.2.2 Prevention treatment
5.2.2.1 Vaccines
5.2.3 Diagnostic tests
5.2.3.1 Laboratory tests for viral antigens
5.2.3.2 Serological tests
5.2.4 Y-o-Y Growth Analysis, By Diagnosis
5.2.5 Market Attractiveness Analysis, By Diagnosis
5.2.6 Market Share Analysis, By Diagnosis
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Clinical forms
6.1.3.3 By Diagnosis
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Clinical forms
6.1.4.3 By Diagnosis
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Clinical forms
6.1.5.3 By Diagnosis
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Veterinary Serum and Vaccine Research Institute
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Onderstepoort Biological Products SOC
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
